List of Ukoniq drug patents

Ukoniq is owned by Tg Theraps.

Ukoniq contains Umbralisib Tosylate.

Ukoniq has a total of 8 drug patents out of which 0 drug patents have expired.

Ukoniq was authorised for market use on 05 February, 2021.

Ukoniq is available in tablet;oral dosage forms.

Ukoniq can be used as relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen, relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy.

Drug patent challenges can be filed against Ukoniq from February, 2025.

The generics of Ukoniq are possible to be released after 26 May, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150579 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10570142 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US9969740 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

US10414773 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9669033 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10981919 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10072013 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10947244 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 5, 2026

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 05 February, 2021

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic